Volitionrx Limited

VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

VolitionRx reports 240% revenue growth, eyes expansion in veterinary diagnostics

VolitionRx reported strong revenue growth in 2022 but faced a net loss due to higher costs, emphasizing the need for cost management.
The company's focus on commercializing its Nu.Q platform and expanding into veterinary diagnostics presents growth opportunities.
While challenges like increased expenditures and competition exist, VolitionRx's strategic partnerships and product pipeline position it for future success.
Exploring new applications of NETosis technology in animal health and upcoming investor events highlight potential growth avenues for VolitionRx.

VolitionRx reports robust Q1 results, eyes growth in cancer testing

VolitionRx Limited's Q1 2023 performance reflects strong financials, strategic partnerships, and promising revenue from innovative cancer testing products.
The company's strengths include financial stability, strategic collaborations, and growth potential in the veterinary and cancer testing markets.
Challenges in managing expenses, sustaining revenue growth, and strategic focus require careful navigation for continued success.
Opportunities abound in leveraging partnerships, exploring new markets, and proactive initiatives for future growth and market expansion.

VolitionRx reports robust Q2 earnings, poised for growth in cancer diagnostics

VolitionRx Limited delivered a strong performance in Q2 2023, marked by significant revenue growth and a solid financial position, underpinned by cash reserves and milestone payments.
The company's focus on advancing Nu.Q technology, expanding partnerships, and making progress in cancer research bodes well for future growth and innovation.
While facing challenges in scaling sales efforts and managing R&D expenses, VolitionRx has opportunities to drive revenue growth through strategic partnerships and market expansion.

VolitionRx reports robust revenue growth and global expansion opportunities

VolitionRx Limited's Q3 2023 performance showcased strong revenue growth and global expansion in Nu.Q Vet Cancer Test sales.
While facing challenges in regulatory timelines and funding, the company's strategic strengths lie in its innovative products and prudent financial approach.
Opportunities in new product launches, market education, and global expansion position VolitionRx for continued growth and breakthroughs in cancer detection.

VolitionRx reports stellar revenue growth, eyes global expansion with strategic partnerships

VolitionRx Limited's Q4 2023 earnings call highlighted robust revenue growth, strong cash position, and strategic partnerships driving expansion. While facing challenges in financing and operational efficiency, the company's focus on innovative technologies and global market penetration positions it well for future growth and partnerships.

Volitionrx reports revenue growth and eyes cash flow positivity by 2025

Volitionrx Limited (VNRX) is on track for growth with strong revenue performance, successful product launches, and a focus on achieving cash flow positivity. The company faces challenges in expense control and funding strategies but has opportunities in upcoming data releases and licensing deals.

Volitionrx reports robust Q3 revenue growth and strategic advancements

Volitionrx Limited demonstrated strong performance in revenue growth, innovation, and financial progress.
Key strengths include successful product sales, research advancements, and strategic financial planning.
Challenges in market dynamics and cost management require strategic focus and operational efficiency improvements.
Opportunities for growth exist in market expansion, cost optimization, new partnerships, and research publications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Volition to participate in the upcoming 14th Annual LifeSci Partners Corporate Access Event on January 15 th, 2025 at the Beacon Grand Hotel in San Francisco. HENDERSON, Nev.

VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants

HENDERSON, Nev. , Dec. 10, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which shows that its Nu.Q® Cancer Test differentiated between malignant and benign pulmonary nodules, found by Low Dose CT (LDCT) scan, in patients suspected of lung cancer.

Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening

Up to $1.9 million up front with up to an additional $2.7 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants HENDERSON, Nev , Dec. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into definitive agreements for the purchase and sale of (i) 445,648 shares of its common stock to certain directors and executive officers of the Company (the "Insiders") at an offering price of $0.5722 per share, and (ii) 2,857,389 shares of its common stock, together with common stock purchase warrants, composed of Form A warrants to purchase up to 2,857,389 shares of common stock and Form B warrants to purchase up to 1,428,693 shares of common stock (collectively, the "Warrants"), to other investors at a combined offering price of $0.5722 per share and accompanying warrants. The Form A warrants and Form B warrants have an exercise price per share of $0.5722 and $0.71525, respectively, are exercisable immediately, and expire five years from the issuance date.

VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering

VolitionRx Limited (NYSE:VNRX ) Q3 2024 Earnings Conference Call November 15, 2024 8:30 AM ET Company Participants Louise Batchelor - Chief Marketing & Communications Officer Tom Butera - CEO, Volition Veterinary Diagnostic Development Andrew Retter - Chief Medical Officer Terig Hughes - CFO Cameron Reynolds - President & CEO Conference Call Participants Jason Kolbert - D. Boral Capital Ilya Zubkov - Freedom Broker Steven Ralston - Zacks Investment Research Bruce Jackson - The Benchmark Company Operator Good day, ladies and gentlemen.

VolitionRx Limited (VNRX) Q3 2024 Earnings Call Transcript

Conference call to discuss financial and operational results scheduled for Friday, November 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.

VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update

Conference call to take place on Friday, November 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.

VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update

HENDERSON, Nev. , Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024.

Volition Appoints Timothy I. Still as Chairman

HENDERSON, Nev. , Oct. 31, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has published a report , from its 'NETs in sepsis management' symposium at ESICM Lives 2024 last month, which concluded that Nu.Q® NETs could be used to predict patients at greater risk of deteriorating from sepsis.

Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating

HENDERSON, Nev. , Oct. 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to expound new data, presented at ESICM LIVES 2024, the annual congress of the European Society of Intensive Care Medicine, earlier this week.

Volition to share new 'NETs in sepsis management' data insights at upcoming webinar

HENDERSON, Nev. , Oct. 3, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is hosting a symposium at ESICM Lives 2024 in Barcelona on October 7, 2024, during which experts from across the globe will present findings from large, independent studies regarding the potential of using Nu.Q® NETs to determine a 'treatable trait' to enhance sepsis management.

Volition hosts NETs in sepsis management symposium at ESICM Lives 2024

HENDERSON, Nev. , Sept. 30, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr. Ethel Rubin to its board of directors, as an independent director, effective September 30, 2024.

Volition Appoints Dr. Ethel Rubin as an Independent Director

HENDERSON, Nev. , Sept. 11, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, hosted a Key Opinion Leader ("KOL") roundtable in Paris this weekend and brought together some of the world's leading experts in sepsis to explore the potential of using Volition's Nu.Q® NETs technology effectively in clinical practice.

Volition Hosts KOL Roundtable on Sepsis

VolitionRx Limited (NYSE:VNRX ) Q2 2024 Earnings Conference Call August 15, 2024 8:30 AM ET Company Participants Louise Batchelor - Chief Marketing and Communications Officer Cameron Reynolds - President and CEO Terig Hughes - CFO Andrew Retter - CMO Gael Forterre - CCO Conference Call Participants Bruce Jackson - The Benchmark Company Ilya Zubkov - Freedom Broker Steven Ralston - Zacks Small-Cap Research Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the VolitionRx Limited's Second Quarter 2024 Earnings Conference Call.

VolitionRx Limited (VNRX) Q2 2024 Earnings Call Transcript

Conference call to discuss financial and operational results scheduled for Thursday, August 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.

VolitionRx Limited Announces Second Quarter 2024 Financial Results and Business Update

$7 million upfront with up to an additional $14.5 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants HENDERSON, Nev. , Aug. 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into definitive agreements for the purchase and sale of 12,727,273 shares of its common stock (or common stock equivalents in lieu thereof) and milestone-linked warrants, composed of series A warrants to purchase up to 12,727,273  shares of common stock and series B warrants to purchase up to 12,727,273 shares of common stock, at an offering price of $0.55 per share (or common stock equivalent in lieu thereof) and accompanying warrants.

VolitionRx Announces Pricing of up to $21.5 Million Registered Direct Offering

Conference call to take place on Thursday August 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.

VolitionRx Limited Schedules Second Quarter 2024 Earnings Conference Call and Business Update

HENDERSON, Nev. , July 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed PharmaVentures Ltd ("PharmaVentures"), a leading transaction advisory firm, to provide strategic advice and transactional support on the out-license of Volition's expanding oncology portfolio.

Volition appoints PharmaVentures for Capture PCR™ and oncology portfolio licensing

HENDERSON, Nev. , June 27, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a mid-year review to stockholders, ahead of its Annual Meeting of Stockholders to be held on July 2, 2024.

VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting

Nexalin Technology Inc

ORLANDO, FL / ACCESSWIRE / June 14, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) ("Nexalin") and VolitionRX Limited (NYSE American:VNRX) ("Volition") on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 15, at 7 p.m. Eastern Time (ET).

Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

HENDERSON, Nevada , May 29, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today that Cameron Reynolds, President and Group Chief Executive Officer, will present and be available for one-to-one meetings at the Jefferies Global Healthcare Conference in New York City. Presentation Details: Date: Wednesday, June 5, 2024 Time: 3.30 pm ET (Track 3) Cameron Reynolds, President and Group CEO of Volition, said: "We are dedicated to improving outcomes for people and animals with life-altering diseases such as sepsis and cancer through earlier detection, disease and treatment monitoring.

VolitionRx Limited to Present at Jefferies Global Healthcare Conference

VolitionRx Limited (NYSE:VNRX ) Q1 2024 Results Conference Call May 14, 2024 8:30 AM ET Company Participants Cameron Reynolds - President, CEO Terig Hughes - CFO Andrew Retter - CMO Gael Forterre - CCO Louise Batchelor - Chief Marketing & Communications Officer Conference Call Participants Bruce Jackson - Benchmark Company Tim Moore - EF Hutton Ilya Zubkov - Freedom Broker Steven Ralston - Zacks Richard Deutsch - Sutter Securities Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to VolitionRx Limited First Quarter 2024 Earnings Conference Call.

VolitionRx Limited (VNRX) Q1 2024 Earnings Call Transcript

Conference call to discuss financial and operational results scheduled for Tuesday, May 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.

VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update

Conference call to take place on Tuesday May 14 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.

VolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business Update

HENDERSON, Nev. , April 23, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® Vet Cancer Test is now available in-clinic to veterinarians across the U.S and Europe through Antech, a leading veterinary diagnostics company.

Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech

VolitionRx Limited (VNRX) Q4 2023 Earnings Call Transcript

News for Volitionrx Limited Stock (VNRX)